Long-Term Follow-Up Result of Hydroxyurea Chemotherapy for Recurrent Meningiomas.
10.3340/jkns.2012.52.6.517
- Author:
Min Su KIM
1
;
Dong Woo YU
;
Young Jin JUNG
;
Sang Woo KIM
;
Chul Hoon CHANG
;
Oh Lyong KIM
Author Information
1. Department of Neurosurgery, College of Medicine, Yeungnam University, Daegu, Korea. olkim@med.yu.ac.kr
- Publication Type:Original Article
- Keywords:
Meningioma;
Chemotherapy;
Hydroxyurea;
Recurrence
- MeSH:
Apoptosis;
Disease Progression;
Female;
Follow-Up Studies;
Humans;
Hydroxyurea;
Magnetic Resonance Imaging;
Male;
Meningioma;
Physical Examination;
Recurrence;
Reoperation;
Ribonucleotide Reductases
- From:Journal of Korean Neurosurgical Society
2012;52(6):517-522
- CountryRepublic of Korea
- Language:English
-
Abstract:
OBJECTIVE: Meningiomas represent 18-20% of all intracranial tumors and have a 20-50% 10-year recurrence rate, despite aggressive surgery and irradiation. Hydroxyurea, an inhibitor of ribonucleotide reductase, is known to inhibit meningioma cells by induction of apoptosis. We report the long-term follow-up result of hydroxyurea therapy in the patients with recurrent meningiomas. METHODS: Thirteen patients with recurrent WHO grade I or II meningioma were treated with hydroxyurea (1000 mg/m2/day orally divided twice per day) from June 1998 to February 2012. Nine female and 4 male, ranging in age from 32 to 83 years (median age 61.7 years), were included. Follow-up assessment included physical examination, computed tomography, and magnetic resonance imaging (MRI). Standard neuro-oncological response criteria (Macdonald criteria) were used to evaluate the follow-up MRI scans. The treatment was continued until there was objective disease progression or onset of unmanageable toxicity. RESULTS: Ten of the 13 patients (76.9%) showed stable disease after treatment, with time to progression ranging from 8 to 128 months (median 72.4 months; 6 patients still accruing time). However, there was no complete response or partial response in any patients. Three patients had progressive disease after 88, 89, 36 months, respectively. There was no severe (Grade III-IV) blood systemic disorders and no episodes of non-hematological side effects. CONCLUSION: This study showed that hydroxyurea is a modestly active agent against recurrent meningiomas and can induce long-term stabilization of disease in some patients. We think that hydroxyurea treatment is well tolerated and convenient, and could be considered as an alternative treatment option in patients with recurrent meningiomas prior to reoperation or radiotherapy.
